What is Pseudoxanthoma elasticum?
Pseudoxanthoma elasticum (PXE) is a rare genetic connective tissue disorder that affects the elastic fibers in the skin, eyes, and blood vessels. The condition causes progressive calcification and fragmentation of elastic fibers, leading to characteristic yellowish skin papules, vision problems, and cardiovascular complications. PXE affects approximately 1 in 50,000 people worldwide, with symptoms typically appearing in childhood or early adulthood. While there is currently no cure, early diagnosis and appropriate management can help prevent serious complications and improve quality of life.
Key statistics
| Prevalence | 1 in 50,000 people worldwide |
| Age of onset | Childhood to early adulthood (typically 10-30 years) |
| Gender distribution | Affects males and females equally |
| Carrier frequency | Approximately 1 in 112 people carry one copy of the mutated gene |
Symptoms
Primary symptoms: Yellow skin papules, angioid retinal streaks, vision loss, vascular calcification, gastrointestinal bleeding, cardiovascular complications.
The symptoms of PXE typically develop gradually and affect multiple organ systems. Skin manifestations are often the first noticeable signs, appearing as small, yellow, pebbled papules that create a “cobblestone” texture, particularly on the neck, armpits, groin, and inner thighs. These lesions may be cosmetically concerning but are generally not painful.
Eye complications include angioid streaks – irregular dark lines radiating from the optic disc caused by breaks in Bruch’s membrane. These can lead to choroidal neovascularization, retinal bleeding, and progressive vision loss. Some patients may experience sudden vision changes due to retinal hemorrhages.
Cardiovascular symptoms develop due to calcification of arterial walls, leading to reduced elasticity and increased risk of hypertension, coronary artery disease, and peripheral vascular disease. Patients may experience claudication (leg pain during walking), reduced exercise tolerance, or chest pain.
Gastrointestinal manifestations can include bleeding from the stomach or intestines due to blood vessel fragility, which may present as dark stools, vomiting blood, or anemia from chronic blood loss.
Causes and risk factors
PXE is caused by mutations in the ABCC6 gene, which provides instructions for making a protein called ABCC6 transporter. This protein is primarily found in liver and kidney cells and plays a crucial role in transporting substances across cell membranes, particularly those involved in preventing calcium and phosphate deposits in elastic fibers.
The condition follows an autosomal recessive inheritance pattern, meaning a person must inherit two copies of the mutated gene (one from each parent) to develop PXE. Parents who each carry one copy of the mutation typically do not show symptoms but have a 25% chance of having an affected child with each pregnancy.
There are no known environmental risk factors that cause PXE, as it is purely genetic. However, certain lifestyle factors may influence the progression of complications, particularly cardiovascular disease risk factors such as smoking, high blood pressure, and diabetes.
Prevention
Since PXE is a genetic condition, it cannot be prevented through lifestyle modifications or environmental changes. However, genetic counseling and testing can help families understand their risk and make informed reproductive decisions.
Carrier testing is available for family members of affected individuals, and preimplantation genetic diagnosis (PGD) may be an option for couples where both partners are carriers. Prenatal testing through chorionic villus sampling or amniocentesis can detect PXE in developing fetuses.
While the condition itself cannot be prevented, early identification allows for proactive monitoring and management to prevent or delay complications, particularly vision loss and cardiovascular disease.
Complications
Without proper monitoring and management, PXE can lead to serious complications affecting multiple organ systems. Vision complications are among the most concerning, with progressive vision loss occurring in approximately 70% of patients. Sudden vision loss from retinal hemorrhages can occur, and some patients may develop legal blindness.
Cardiovascular complications include accelerated atherosclerosis, coronary artery disease, stroke, and peripheral artery disease. The calcification of arterial walls increases the risk of heart attack and stroke, particularly in younger patients who would not typically be at risk.
Gastrointestinal bleeding can range from mild, chronic blood loss leading to anemia to severe, life-threatening hemorrhages requiring emergency intervention. This bleeding typically occurs from small blood vessels in the stomach and intestines that become fragile due to elastic fiber abnormalities.
Some patients may also experience psychological complications related to the visible skin changes and the chronic nature of the condition, including anxiety, depression, and social withdrawal.
Diagnosis
Diagnosing PXE requires a combination of clinical examination, specialized imaging, and genetic testing. The diagnostic process often involves multiple specialists, including dermatologists, ophthalmologists, and genetic counselors.
Clinical examination focuses on identifying characteristic skin lesions, particularly the yellow papules in typical locations. A thorough family history is important given the genetic nature of the condition.
Ophthalmologic evaluation includes dilated fundus examination to identify angioid streaks, optical coherence tomography (OCT) to assess retinal structure, and fluorescein angiography to evaluate blood vessel abnormalities in the retina.
Genetic testing for ABCC6 gene mutations provides definitive diagnosis. Comprehensive gene sequencing can identify the specific mutations responsible for the condition.
Skin biopsy may be performed to examine elastic fibers under microscopic examination, showing characteristic calcification and fragmentation. Special stains such as von Kossa stain highlight calcium deposits in elastic fibers.
Cardiovascular assessment includes electrocardiogram (ECG), echocardiogram, and vascular imaging studies to evaluate the extent of arterial calcification and cardiovascular involvement.
Treatment
Currently, there is no cure for PXE, and treatment focuses on managing symptoms and preventing complications. A multidisciplinary approach involving dermatologists, ophthalmologists, cardiologists, and other specialists is essential.
Eye care includes regular monitoring with dilated eye exams every 6-12 months, and immediate evaluation for any sudden vision changes. Anti-VEGF injections such as ranibizumab or bevacizumab may be used to treat choroidal neovascularization. Low-vision aids and rehabilitation services can help patients adapt to vision changes.
Cardiovascular management involves controlling risk factors through lifestyle modifications and medications. Atorvastatin and other statins may be prescribed to manage cholesterol levels. Blood pressure control with lisinopril or other ACE inhibitors is important. Aspirin may be recommended for cardiovascular protection.
Experimental treatments under investigation include magnesium supplementation and dietary phosphate restriction, though evidence remains limited. Some studies are exploring the use of bisphosphonates and other agents that may influence calcium metabolism.
Prognosis
The prognosis for PXE varies significantly depending on the severity of organ system involvement and how early complications are detected and managed. Life expectancy can be normal with appropriate care, though cardiovascular complications may reduce lifespan in some patients.
Vision prognosis depends on early detection and treatment of complications. With regular monitoring and prompt treatment of choroidal neovascularization, many patients maintain functional vision throughout their lives. However, progressive vision loss remains a significant concern, with some patients developing severe visual impairment.
Cardiovascular prognosis has improved with better understanding of the condition and proactive management of risk factors. Early intervention can help prevent or delay serious cardiovascular events, though ongoing monitoring remains essential throughout life.
Quality of life can be maintained through appropriate medical care, support services, and adaptive strategies for daily living activities.
Quality of life
Living with PXE requires adaptations and ongoing medical care, but many patients lead fulfilling lives with proper support and management. Regular exercise, as approved by healthcare providers, can help maintain cardiovascular health while avoiding activities that may increase bleeding risk.
Dietary considerations may include limiting foods high in calcium and phosphate, though specific dietary restrictions should be discussed with healthcare providers. A heart-healthy diet low in saturated fats and sodium is generally recommended.
Sun protection is important for skin health, and patients should use sunscreen and protective clothing to prevent skin damage. Gentle skincare routines can help manage skin changes.
Mental health support is crucial, as the visible nature of skin changes and potential vision loss can impact self-esteem and emotional well-being. Counseling, support groups, and connecting with other patients through organizations like PXE International can provide valuable emotional support.
Workplace and educational accommodations may be necessary for those experiencing vision changes, including improved lighting, magnification tools, and flexible work arrangements.
Pregnancy and fertility
PXE does not typically affect fertility in men or women. However, pregnancy requires careful monitoring due to potential complications related to cardiovascular involvement and bleeding risks.
Pregnant women with PXE should receive high-risk obstetric care with regular monitoring of blood pressure and cardiovascular status. The increased blood volume and cardiac demands of pregnancy may exacerbate cardiovascular symptoms in some patients.
Genetic counseling is essential for family planning, as each child has a 25% chance of being affected if both parents are carriers, or a 50% chance of being a carrier if one parent has PXE and the other is a carrier.
Most medications used to manage PXE complications can be safely continued during pregnancy, though specific medications should be reviewed with healthcare providers. Some treatments may require modification or temporary discontinuation.
Children
PXE can affect children, though symptoms may be subtle in early childhood and become more apparent during adolescence. Skin changes are often the first manifestation, appearing as small yellow papules in flexural areas.
Regular eye examinations are crucial in children with PXE, as angioid streaks may be present even when vision appears normal. Early detection allows for prompt intervention if complications develop.
School accommodations may be necessary if vision problems develop, including preferential seating, large-print materials, and assistive technology. Physical education activities should be modified to avoid high-impact sports that may increase bleeding risk.
Psychosocial support is important for children and adolescents dealing with visible skin changes and potential vision problems. Family counseling and peer support can help children develop coping strategies and maintain self-confidence.
When to see a doctor
Immediate medical attention is needed for sudden vision changes, including blurred vision, dark spots, flashing lights, or curtain-like vision loss, as these may indicate retinal bleeding or detachment requiring urgent treatment.
Cardiovascular symptoms such as chest pain, shortness of breath, or severe leg pain during walking warrant prompt evaluation. Signs of gastrointestinal bleeding, including dark or bloody stools, vomiting blood, or unexplained weakness and fatigue, require immediate medical care.
Routine care should include regular ophthalmologic examinations every 6-12 months, annual cardiovascular assessment, and periodic evaluation by a dermatologist familiar with PXE. Any new or changing skin lesions should be evaluated.
Regional context
Specific prevalence data for PXE in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean is limited. The condition appears to occur across all ethnic groups worldwide, though some founder mutations may be more common in certain populations.
Healthcare providers in the region are encouraged to contribute case reports and epidemiological data to the Global Medical Journal to improve understanding of PXE prevalence and characteristics in these populations. Collaboration with international PXE research networks can enhance diagnostic capabilities and treatment options for regional patients.
Research and clinical trials
Current research focuses on understanding the molecular mechanisms of ABCC6 protein function and developing targeted therapies. Studies are investigating the role of vitamin K metabolism, anti-calcification agents, and novel therapeutic approaches.
Clinical trials are exploring treatments including magnesium supplementation, dietary phosphate restriction, and experimental drugs targeting calcium metabolism pathways. Gene therapy approaches are being investigated in laboratory studies.
Patients interested in clinical trials can search ClinicalTrials.gov for “pseudoxanthoma elasticum” to find current studies. The PXE International patient organization maintains information about ongoing research opportunities and facilitates connections between patients and researchers.
Recent research has advanced understanding of the relationship between ABCC6 function and mineral metabolism, opening new avenues for therapeutic intervention.
Frequently asked questions
Is PXE contagious or inherited?
PXE is a genetic condition inherited in an autosomal recessive pattern. It is not contagious and cannot be transmitted through contact. Both parents must be carriers for a child to be affected.
Will I definitely lose my vision if I have PXE?
Not all patients with PXE experience significant vision loss. With regular monitoring and prompt treatment of complications, many patients maintain functional vision throughout their lives. Early detection and treatment of eye problems significantly improve outcomes.
Can lifestyle changes slow the progression of PXE?
While lifestyle changes cannot cure PXE, maintaining cardiovascular health through diet, exercise, and avoiding smoking may help reduce complications. Some research suggests dietary modifications may be beneficial, though specific recommendations should be discussed with healthcare providers.
Should my family members be tested for PXE?
Genetic counseling is recommended for family members to discuss testing options. Siblings have a 25% chance of being affected and a 50% chance of being carriers. Genetic testing can provide important information for family planning and health monitoring.
Are there any experimental treatments available?
Several experimental treatments are being studied, including magnesium supplementation and dietary modifications. Patients should discuss potential participation in clinical trials with their healthcare providers and consider contacting PXE International for information about research opportunities.
Support and resources
Patient organizations:
– PXE International: https://pxe.org
– National Organization for Rare Disorders (NORD): https://rarediseases.org
– Orphanet: https://orpha.net
– EURORDIS (European Rare Disease Organisation): https://eurordis.org
Medical resources:
– GeneReviews (NCBI): Comprehensive genetic information
– ClinicalTrials.gov: Current research studies
– Global Genes: https://globalgenes.org
Related conditions
Ehlers-Danlos syndrome
Marfan syndrome
Osteogenesis imperfecta
Cutis laxa
Arterial calcification due to CD73 deficiency
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Pseudoxanthoma elasticum.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/pseudoxanthoma-elasticum/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?